Appendix E Tables and Figures

Timothy J Wilt; Tatyana Shamliyan; Aasma Shaukat; Brent C Taylor; Roderick MacDonald; Jian-Min Yuan; James R Johnson; James Tacklind; Indulis Rutks; Robert L Kane

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Wilt TJ, Shamliyan T, Shaukat A, et al. Management of Chronic Hepatitis B. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Oct. (Evidence Reports/Technology Assessments, No. 174.)

This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Management of Chronic Hepatitis B.

Show details

Contents

< Prev Next >

Appendix E Tables and Figures

Figure 1. Flow Chart for Key Questions

Figure 2. Effects of interferon alfa-2b and reverse transcriptase inhibitors on clinical outcomes compared to placebo or no active treatment—Relative risk from four individual RCTs

Figure 3. Comparative effectiveness of interferon alfa-2b and reverse transcriptase inhibitors on mortality, results from individual randomized controlled clinical trials

Figure 4. Comparative effectiveness of active drugs on clinical outcomes, results from individual RCTs

Figure 5. Effects of active treatments compared to placebo on HBsAg loss at the end of the treatment (results from individual RCTs )

Figure 6. Effects of active treatments compared to placebo on HBsAg loss at followup off the treatment (results from individual RCTs)

Figure 7. Comparative effectiveness of active treatments on HBsAg loss at the end of the treatments (results from individual RCTs)

Figure 8. Comparative effectiveness of active treatments on HBsAg loss at followup off the treatments (results from individual RCTs)

Figure 9. HBsAg loss combined with other criteria of resolved hepatitis B at followup off the therapy (results from individual RCTs)

Figure 10. HBV DNA loss at the end of the drug therapies for chronic hepatitis B (significant risk differences from individual RCTs and pooled with random effects model)

Figure 11. HBV DNA loss at followup off the drug therapies for chronic hepatitis B (significant risk differences from individual RCTs and pooled with random effects model)

Figure 12. Significant effects on HBeAg loss for chronic hepatitis B (significant risk differences from individual RCTs and pooled with random effects model)

Figure 13. Significant relative risk of virological, histological and biochemical outcomes after drug therapies for chronic hepatitis B (results from individual RCT and pooled consistent results using random effects model)

Figure 14. Significant effects on HBeAg seroconversion for chronic hepatitis B (significant risk differences from individual RCTs and pooled with random effects model)

Figure 15. Significant effects on combined virological and biochemical outcomes at the end of the drug therapies for chronic hepatitis B (significant risk differences from individual RCTs and pooled with random effects model)

Figure 16. Significant effects on combined virological and biochemical outcomes at follow up after drug therapies for chronic hepatitis B (significant risk differences from individual RCTs and pooled with random effects model)

Figure 17. Histological outcomes at the end of the drug therapies for chronic hepatitis B (significant risk differences from individual RCTs and pooled with random effects model)

Figure 18. ALT normalization at the end of the drug therapies for chronic hepatitis B (significant risk differences from individual RCTs and pooled with random effects model)

Figure 19. ALT normalization at followup off the drug therapies for chronic hepatitis B (significant risk differences from individual RCTs and pooled with random effects model)

Figure 20. Combined outcomes at the end of the treatments by baseline ALT levels (individual RCTs)

Figure 21. The effects of lamivudine, 100mg/day compared to placebo at the end of the treatment depending on baseline ALT level (4 lamivudine-controlled Phase III trials)

Figure 22. HBV DNA loss at followup off the drug therapies for chronic hepatitis B by patient pretreatment status, baseline HBeAg positivity, and the proportion of the patients with baseline cirrhosis, the results from individual studies

Figure 23. HBeAg loss and seroconversion at followup off drug therapies for chronic hepatitis B by patient pretreatment status, baseline HBeAg positivity, and the proportion of the patients with baseline cirrhosis, results from individual studies

Figure 24. ALT normalization at followup off drug therapies for chronic hepatitis B by patient pretreatment status, baseline HBeAg positivity, and the proportion of the patients with baseline cirrhosis, results from individual studies

Table E1. Evidence table: Observational studies of the natural history of chronic hepatitis B in adults

Table E2. Evidence table: Randomized controlled trials for treatment of hepatitis B

Table E3. Reported clinical and intermediate outcomes after comparisons of antiviral drugs for chronic hepatitis B (randomized controlled clinical trials)

Table E4. Evidence tables of the effects of antiviral drugs on patient outcomes (individual randomized controlled clinical trials)

Table E5. Summary tables of the effects of drug therapies for chronic hepatitis B on outcomes

Table E6. Levels of viral load, biochemical, or histologic outcomes after antiviral drugs in adults with chronic hepatitis B

Table E7. Number of subjects experiencing adverse events from RCTs

Table E8. Number of subjects with laboratory abnormalities from RCTS

Table E9. Evidence tables of the effects of drug interventions on outcomes among patient subgroups (individual RCTs)

Table E10. Summary tables of the effects of therapies for CHB in patient subpopulations by baseline status of chronic hepatitis B

Table E11. Rates of clinical, intermediate, and adverse outcomes after antiviral treatment / no treatment by baseline HBeAg status at the end of treatment and at followup off treatment. (results from individual RCTs and pooled analyses with random effects models. Rates pooled from RCTs that reported outcomes independent of active or control regime)

Table E12. Summary of study IDs meeting eligibility for question 4

Table E13. Evidence table of the studies that examined the association between changes in intermediate outcomes to predict treatment effectiveness (n=4)

Table E14. Other baseline factors as predictors of outcomes, and other outcomes (n=3)

Table E15. Ongoing interventional randomized studies in patients with chronic hepatitis B (underlined outcomes assessment in patient subpopulations relevant to question 3)

Table E16. Completed unpublished RCTs in patients with chronic hepatitis B

References for Appendix E

1.: Livingston SE, Simonetti JP, McMahon BJ. et al. Hepatitis B virus genotypes in Alaska Native people with hepatocellular carcinoma: preponderance of genotype F.[see comment] Journal of Infectious Diseases. 2007 Jan 1;195(1):5–11. [PubMed: 17152003]
2.: McMahon BJ, Holck P, Bulkow L. et al. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus.[see comment] Annals of Internal Medicine. 2001 Nov 6;135(9):759–68. [PubMed: 11694101]
3.: McMahon BJ, Bulkow L, Harpster A. et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology. 2000 Oct;32(4 Pt 1):842–6. [PubMed: 11003632]
4.: McMahon BJ, Alberts SR, Wainwright RB. et al. Hepatitis B-related sequelae. Prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Archives of Internal Medicine. 1990 May;150(5):1051–4. [PubMed: 2158773]
5.: Tong MJ, Blatt LM, Kao JH. et al. Basal core promoter T1762/A1764 and precore A1896 gene mutations in hepatitis B surface antigen-positive hepatocellular carcinoma: a comparison with chronic carriers. Liver Int. 2007 Dec;27(10):1356–63. [PMC free article: PMC2229667] [PubMed: 17900245]
6.: Tong MJ, Blatt LM, Kao JH. et al. Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma. World J Gastroenterol. 2006 Nov 7;12(41):6620–6. [PMC free article: PMC4125666] [PubMed: 17075974]
7.: Tong MJ, Blatt LM, Tyson KB. et al. Death from liver disease and development of hepatocellular carcinoma in patients with chronic Hepatitis B virus infection: a prospective study. Gastroenterology & Hepatology. 2006 Jan;2(1):41–7. [PMC free article: PMC5307261] [PubMed: 28210196]
8.: Tong MJ, Blatt LM, Kao VW. et al. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. Journal of Gastroenterology & Hepatology. 2001 May;16(5):553–9. [PubMed: 11350553]
9.: Schiodt FV, Davern TJ, Shakil AO. et al. Viral hepatitis-related acute liver failure. Am J Gastroenterol. 2003 Feb;98(2):448–53. [PubMed: 12591067]
10.: Thio CL, Seaberg EC, Skolasky R Jr. et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002 Dec 14;360(9349):1921–6. [PubMed: 12493258]
11.: Abiad H, Ramani R, Currie JB. et al. The natural history of hepatitis D virus infection in Illinois state facilities for the developmentally disabled. American Journal of Gastroenterology. 2001 Feb;96(2):534–40. [PubMed: 11232702]
12.: Nomura A, Stemmermann GN, Chyou PH. et al. Hepatitis B and C virus serologies among Japanese Americans with hepatocellular carcinoma. Journal of Infectious Diseases. 1996 Jun;173(6):1474–6. [PubMed: 8648223]
13.: Norman JE, Beebe GW, Hoofnagle JH. et al. Mortality follow-up of the 1942 epidemic of hepatitis B in the U.S. Army. Hepatology. 1993 Oct;18(4):790–7. [PubMed: 8406352]
14.: Weissberg JI, Andres LL, Smith CI. et al. Survival in chronic hepatitis B. An analysis of 379 patients. Ann Intern Med. 1984 Nov;101(5):613–6. [PubMed: 6486592]
15.: Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology. 1995 Aug;22(2):432–8. [PubMed: 7543434]
16.: Amin J, Dore GJ, O'Connell DL. et al. Cancer incidence in people with hepatitis B or C infection: a large community-based linkage study. Journal of Hepatology. 2006 Aug;45(2):197–203. [PubMed: 16684579]
17.: Konopnicki D, Mocroft A, de Wit S. et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort.[see comment] AIDS. 2005 Mar 24;19(6):593–601. [PubMed: 15802978]
18.: Ribes J, Cleries R, Rubio A. et al. Cofactors associated with liver disease mortality in an HBsAg-positive Mediterranean cohort: 20 years of follow-up. International Journal of Cancer. 2006 Aug 1;119(3):687–94. [PubMed: 16496403]
19.: Crook PD, Jones ME, Hall AJ. et al. Mortality of hepatitis B surface antigen-positive blood donors in England and Wales. International Journal of Epidemiology. 2003 Feb;32(1):118–24. [PubMed: 12690022]
20.: Chan HL, Tse CH, Mo F. et al. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol. 2008 Jan 10;26(2):177–82. [PubMed: 18182659]
21.: Chen JG, Kuang SY, Egner PA. et al. Acceleration to death from liver cancer in people with hepatitis B viral mutations detected in plasma by mass spectrometry. Cancer Epidemiology, Biomarkers & Prevention. 2007 Jun;16(6):1213–8. [PubMed: 17548687]
22.: Chen G, Lin W, Shen F. et al. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. American Journal of Gastroenterology. 2006 Aug;101(8):1797–803. [PubMed: 16817842]
23.: Chen G, Lin W, Shen F. et al. Chronic hepatitis B virus infection and mortality from non-liver causes: results from the Haimen City cohort study. International Journal of Epidemiology. 2005 Feb;34(1):132–7. [PubMed: 15659459]
24.: Evans AA, Chen G, Ross EA. et al. Eight-year follow-up of the 90,000-person Haimen City cohort: I. Hepatocellular carcinoma mortality, risk factors, and gender differences. Cancer Epidemiology, Biomarkers & Prevention. 2002 Apr;11(4):369–76. [PubMed: 11927497]
25.: London WT, Evans AA, McGlynn K. et al. Viral, host and environmental risk factors for hepatocellular carcinoma: a prospective study in Haimen City, China. Intervirology. 1995;38(34):155–61. [PubMed: 8682610]
26.: Chen CJ, Yang HI, Su J. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006 Jan 4;295(1):65–73. [PubMed: 16391218]
27.: Iloeje UH, Yang HI, Su J. et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load.[see comment] Gastroenterology. 2006 Mar;130(3):678–86. [PubMed: 16530509]
28.: Yu MW, Yeh SH, Chen PJ. et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men.[see comment] Journal of the National Cancer Institute. 2005 Feb 16;97(4):265–72. [PubMed: 15713961]
29.: Yu MW, Yang SY, Chiu YH. et al. A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology. 1999 Mar;29(3):697–702. [PubMed: 10051470]
30.: Wang LY, You SL, Lu SN. et al. Risk of hepatocellular carcinoma and habits of alcohol drinking, betel quid chewing and cigarette smoking: a cohort of 2416 HBsAg-seropositive and 9421 HBsAg-seronegative male residents in Taiwan. Cancer Causes & Control. 2003 Apr;14(3):241–50. [PubMed: 12814203]
31.: Yang HI, Lu SN, Liaw YF. et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. New England Journal of Medicine. 2002 Jul 18;347(3):168–74. [PubMed: 12124405]
32.: Yuen MF, Yuan HJ, Wong DK. et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005 Nov;54(11):1610–4. [PMC free article: PMC1774768] [PubMed: 15871997]
33.: Jee SH, Ohrr H, Sull JW. et al. Cigarette smoking, alcohol drinking, hepatitis B, and risk for hepatocellular carcinoma in Korea. Journal of the National Cancer Institute. 2004 Dec 15;96(24):1851–6. [PubMed: 15601641]
34.: Lam CM, Chan AO, Ho P. et al. Different presentation of hepatitis B-related hepatocellular carcinoma in a cohort of 1863 young and old patients - implications for screening. Alimentary Pharmacology & Therapeutics. 2004 Apr 1;19(7):771–7. [PubMed: 15043518]
35.: Tanaka H, Tsukuma H, Yamano H. et al. Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus-positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus. International Journal of Cancer. 2004 Dec 20;112(6):1075–80. [PubMed: 15386355]
36.: Mori M, Hara M, Wada I. et al. Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption, and other factors associated with hepatocellular carcinoma risk in Japan. American Journal of Epidemiology. 2000 Jan 15;151(2):131–9. [PubMed: 10645815]
37.: Yu MW, Hsu FC, Sheen IS. et al. Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. American Journal of Epidemiology. 1997 Jun 1;145(11):1039–47. [PubMed: 9169913]
38.: Tokudome S, Ikeda M, Matsushita K. et al. Hepatocellular carcinoma among female Japanese hepatitis B virus carriers. Hepato-Gastroenterology. 1987 Dec;34(6):246–8. [PubMed: 2828208]
39.: Beasley RP, Hwang LY, Lin CC. et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981 Nov 21;2(8256):1129–33. [PubMed: 6118576]
40.: Zeng M, Mao Y, Yao G. et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology. 2006 Jul;44(1):108–16. [PubMed: 16799983]
41.: Hadziyannis SJ, Tassopoulos NC, Heathcote EJ. et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med. 2003 Feb 27;348(9):800–7. [PubMed: 12606734]
42.: Marcellin P, Chang TT, Lim SG. et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003 Feb 27;348(9):808–16. [PubMed: 12606735]
43.: Peters MG, Hann HwH, Martin P. et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2004 Jan;126(1):91–101. [PubMed: 14699491]
44.: Chan HL, Heathcote EJ, Marcellin P. et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med. 2007 Dec 4;147(11):745–54. [PubMed: 17909201]
45.: Akyildiz M, Gunsar F, Ersoz G. et al. Adefovir dipivoxil alone or in combination with lamivudine for three months in patients with lamivudine resistant compensated chronic hepatitis B. Dig Dis Sci. 2007 Dec;52(12):3444–7. [PubMed: 17431777]
46.: Chan HL, Wang H, Niu J. et al. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. Antivir Ther. 2007;12(3):345–53. [PubMed: 17591024]
47.: Schiff ER, Dienstag JL, Karayalcin S. et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol. 2003 Jun;38(6):818–26. [PubMed: 12763376]
48.: Dienstag JL, Schiff ER, Wright TL. et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999 Oct 21;341(17):1256–63. [PubMed: 10528035]
49.: Tassopoulos NC, Volpes R, Pastore G. et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B.Lamivudine Precore Mutant Study Group. Hepatology. 1999 Mar;29(3):889–96. [PubMed: 10051494]
50.: Lai CL, Chien RN, Leung NW. et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998 Jul 9;339(2):61–8. [PubMed: 9654535]
51.: Liaw YF, Sung JJ, Chow WC. et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004 Oct 7;351(15):1521–31. [PubMed: 15470215]
52.: Jang JW, Choi JY, Bae SH. et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo-lipiodolization. Hepatology. 2006 Feb;43(2):233–40. [PubMed: 16440357]
53.: Ke CZ, Chen Y, Gong ZJ. et al. Dynamic changes of HBV DNA in serum and peripheral blood mononuclear cells of chronic hepatitis patients after lamivudine treatment. World J Gastroenterol. 2006 Jul 7;12(25):4061–3. [PMC free article: PMC4087722] [PubMed: 16810760]
54.: Kim YJ, Kim BG, Jung JO. et al. High rates of progressive hepatic functional deterioration whether lamivudine therapy is continued or discontinued after emergence of a lamivudine-resistant mutant: a prospective randomized controlled study. J Gastroenterol. 2006 Mar;41(3):240–9. [PubMed: 16699858]
55.: Nevens F, Main J, Honkoop P. et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology. 1997 Oct;113(4):1258–63. [PubMed: 9322520]
56.: Lau GK, Piratvisuth T, Luo KX. et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005 Jun 30;352(26):2682–95. [PubMed: 15987917]
57.: Marcellin P, Lau GK, Bonino F. et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2004 Sep 16;351(12):1206–17. [PubMed: 15371578]
58.: Perrillo R, Hann HW, Mutimer D. et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004 Jan;126(1):81–90. [PubMed: 14699490]
59.: Chan HL, Leung NW, Hui AY. et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med. 2005 Feb 15;142(4):240–50. [PubMed: 15710957]
60.: Akyuz F, Kaymakoglu S, Demir K. et al. Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy. Acta Gastroenterol Belg. 2007 Jan–Mar;70(1):20–4. [PubMed: 17619534]
61.: Lu HY, Zhuang LW, Yu YY. et al. Intrahepatic HBV DNA as a predictor of antivirus treatment efficacy in HBeAg-positive chronic hepatitis B patients. World J Gastroenterol. 2007 May 28;13(20):2878–82. [PMC free article: PMC4395644] [PubMed: 17569128]
62.: Shi M, Wang RS, Zhang H. et al. Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations. J Antimicrob Chemother. 2006 Nov;58(5):1031–5. [PubMed: 16987866]
63.: Economou M, Manolakopoulos S, Trikalinos TA. et al. Interferon-alpha plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World J Gastroenterol. 2005 Oct 7;11(37):5882–7. [PMC free article: PMC4479694] [PubMed: 16270403]
64.: Akarca US, Ersoz G, Gunsar F. et al. Interferon-lamivudine combination is no better than lamivudine alone in anti-HBe-positive chronic hepatitis B. Antivir Ther. 2004 Jun;9(3):325–34. [PubMed: 15259895]
65.: Jang MK, Chung YH, Choi MH. et al. Combination of alpha-interferon with lamivudine reduces viral breakthrough during long-term therapy. J Gastroenterol Hepatol. 2004 Dec;19(12):1363–8. [PubMed: 15610309]
66.: Barbaro G, Zechini F, Pellicelli AM. et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol. 2001 Sep;35(3):406–11. [PubMed: 11592603]
67.: Schalm SW, Heathcote J, Cianciara J. et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut. 2000 Apr;46(4):562–8. [PMC free article: PMC1727894] [PubMed: 10716688]
68.: Scotto G, Palumbo E, Fazio V. et al. Efficacy and tolerability of lamivudine alone versus lamivudine plus alpha-interferon for treatment of chronic active hepatitis B in patients with a precore-mutant variant. Infez Med. 2006 Sep;14(3):145–51. [PubMed: 17127828]
69.: Sarin SK, Kumar M, Kumar R. et al. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am J Gastroenterol. 2005 Nov;100(11):2463–71. [PubMed: 16279901]
70.: Santantonio T, Niro GA, Sinisi E. et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol. 2002 Jun;36(6):799–804. [PubMed: 12044531]
71.: Lai CL, Gane E, Liaw YF. et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med. 2007 Dec 20;357(25):2576–88. [PubMed: 18094378]
72.: Lai CL, Leung N, Teo EK. et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology. 2005 Aug;129(2):528–36. [PubMed: 16083710]
73.: Chang TT, Gish RG, de Man R. et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006 Mar 9;354(10):1001–10. [PubMed: 16525137]
74.: Lai CL, Shouval D, Lok AS. et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 2006 Mar 9;354(10):1011–20. [PubMed: 16525138]
75.: Sherman M, Yurdaydin C, Sollano J. et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology. 2006 Jun;130(7):2039–49. [PubMed: 16762627]
76.: Chang TT, Gish RG, Hadziyannis SJ. et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology. 2005 Oct;129(4):1198–209. [PubMed: 16230074]
77.: Lai CL, Rosmawati M, Lao J. et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology. 2002 Dec;123(6):1831–8. [PubMed: 12454840]
78.: Janssen HL, van Zonneveld M, Senturk H. et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005 Jan 8–14;365(9454):123–9. [PubMed: 15639293]
79.: Yalcin K, Degertekin H, Yildiz F. et al. Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B. Clin Infect Dis. 2003 Jun 15;36(12):1516–22. [PubMed: 12802750]
80.: Mutimer D, Naoumov N, Honkoop P. et al. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J Hepatol. 1998 Jun;28(6):923–9. [PubMed: 9672165]
81.: Zhao H, Kurbanov F, Wan MB. et al. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis. 2007 Feb 15;44(4):541–8. [PubMed: 17243057]
82.: Chung YH, Song BC, Lee GC. et al. Individualization of interferon therapy using serum hepatitis B virus DNA to reduce viral relapse in patients with chronic hepatitis B: a randomized controlled trial. Eur J Gastroenterol Hepatol. 2003 May;15(5):489–93. [PubMed: 12702905]
83.: Janssen HL, Gerken G, Carreno V. et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology. 1999 Jul;30(1):238–43. [PubMed: 10385662]
84.: Lampertico P, Del Ninno E, Manzin A. et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology. 1997 Dec;26(6):1621–5. [PubMed: 9398007]
85.: Lopez-Alcorocho JM, Bartolome J, Cotonat T. et al. Efficacy of prolonged interferon-alpha treatment in chronic hepatitis B patients with HBeAb: comparison between 6 and 12 months of therapy. J Viral Hepat. 1997;4(Suppl 1):27–32. [PubMed: 9097275]
86.: Di Bisceglie AM, Fong TL, Fried MW. et al. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B. Am J Gastroenterol. 1993 Nov;88(11):1887–92. [PubMed: 8237937]
87.: Muller R, Baumgarten R, Markus R. et al. Treatment of chronic hepatitis B with interferon alfa-2b. J Hepatol. 1990;11(Suppl 1):S137–40. [PubMed: 2079572]
88.: Hadziyannis S, Bramou T, Makris A. et al. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. J Hepatol. 1990;11(Suppl 1):S133–6. [PubMed: 2079571]
89.: Waked I, Amin M, Abd el Fattah S. et al. Experience with interferon in chronic hepatitis B in Egypt. J Chemother. 1990 Oct;2(5):310–8. [PubMed: 2090770]
90.: Reichen J, Bianchi L, Frei PC. et al. Efficacy of steroid withdrawal and low-dose interferon treatment in chronic active hepatitis B. Results of a randomized multicenter trial. Swiss Association for the Study of the Liver. J Hepatol. 1994 Feb;20(2):168–74. [PubMed: 8006396]
91.: Zarski JP, Causse X, Cohard M. et al. A randomized, controlled trial of interferon alfa-2b alone and with simultaneous prednisone for the treatment of chronic hepatitis B. French Multicenter Group. J Hepatol. 1994 Jun;20(6):735–41. [PubMed: 7930473]
92.: Perez V, Findor J, Tanno H. et al. A controlled trial of high dose interferon, alone and after prednisone withdrawal, in the treatment of chronic hepatitis B: long term follow up. Gut. 1993;34(2 Suppl):S91–4. [PMC free article: PMC1374020] [PubMed: 8314497]
93.: Lok AS, Wu PC, Lai CL. et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology. 1992 Jun;102(6):2091–7. [PubMed: 1587429]
94.: Niederau C, Heintges T, Niederau M. et al. Prospective randomized controlled trial of sequential treatment with corticoids and alpha-interferon versus treatment with interferon alone in patients with chronic active hepatitis B. Eur J Med. 1992 Nov;1(7):396–402. [PubMed: 1341478]
95.: Perez V, Tanno H, Villamil F. et al. Recombinant interferon alfa-2b following prednisone withdrawal in the treatment of chronic type B hepatitis. J Hepatol. 1990;11(Suppl 1):S113–7. [PubMed: 2079567]
96.: Perrillo RP, Schiff ER, Davis GL. et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med. 1990 Aug 2;323(5):295–301. [PubMed: 2195346]
97.: Hadziyannis SJ, Tassopoulos NC, Heathcote EJ. et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006 Dec;131(6):1743–51. [PubMed: 17087951]
98.: Hadziyannis SJ, Tassopoulos NC, Heathcote EJ. et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med. 2005 Jun 30;352(26):2673–81. [PubMed: 15987916]
99.: Izzedine H, Hulot JS, Launay-Vacher V. et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: two double-blind, randomized, placebo-controlled studies. Kidney Int. 2004 Sep;66(3):1153–8. [PubMed: 15327411]
100.: Westland CE, Yang H, Delaney WEt. et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology. 2003 Jul;38(1):96–103. [PubMed: 12829991]
101.: Gish RG, Lok AS, Chang TT. et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007 Nov;133(5):1437–44. [PubMed: 17983800]
102.: Wai CT, Chu CJ, Hussain M. et al. HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology. 2002 Dec;36(6):1425–30. [PubMed: 12447868]
103.: Robson SC, Brice E, van Rensburg C. et al. Safety and efficacy of interferon alpha-2b following prednisone withdrawal in the treatment of chronic viral hepatitis B. A case-controlled, randomised study. S Afr Med J. 1992 Nov;82(5):317–20. [PubMed: 1448711]
104.: Perrillo RP, Lai CL, Liaw YF. et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002 Jul;36(1):186–94. [PubMed: 12085364]
105.: Muller R, Baumgarten R, Markus R. et al. Low dose alpha interferon treatment in chronic hepatitis B virus infection. Gut. 1993;34(2 Suppl):S97–8. [PMC free article: PMC1374022] [PubMed: 8314499]
106.: Leung NW, Lai CL, Chang TT. et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology. 2001 Jun;33(6):1527–32. [PubMed: 11391543]
107.: Dienstag JL, Goldin RD, Heathcote EJ. et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003 Jan;124(1):105–17. [PubMed: 12512035]
108.: Yao GB. Management of hepatitis B in China. J Med Virol. 2000 Jul;61(3):392–7. [PubMed: 10861652]
109.: Honkoop P, de Man RA, Niesters HG. et al. Quantitative hepatitis B virus DNA assessment by the limiting-dilution polymerase chain reaction in chronic hepatitis B patients: evidence of continuing viral suppression with longer duration and higher dose of lamivudine therapy. J Viral Hepat. 1998 Sep;5(5):307–12. [PubMed: 9795914]
110.: Liaw YF, Leung NW, Chang TT. et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology. 2000 Jul;119(1):172–80. [PubMed: 10889166]
111.: Yuen MF, Chow DH, Tsui K. et al. Liver histology of Asian patients with chronic hepatitis B on prolonged lamivudine therapy. Aliment Pharmacol Ther. 2005 Apr 1;21(7):841–9. [PubMed: 15801919]
112.: Yao G, Wang B, Cui Z. et al. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection. Chin Med J (Engl). 1999 May;112(5):387–91. [PubMed: 11593504]
113.: Kweon YO, Goodman ZD, Dienstag JL. et al. Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B. J Hepatol. 2001 Dec;35(6):749–55. [PubMed: 11738102]
114.: Bonino F, Marcellin P, Lau GK. et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut. 2007 May;56(5):699–705. [PMC free article: PMC1942152] [PubMed: 17127704]
115.: Cindoruk M, Karakan T, Unal S. Hepatic steatosis has no impact on the outcome of treatment in patients with chronic hepatitis B infection. J Clin Gastroenterol. 2007 May–Jun;41(5):513–7. [PubMed: 17450036]
116.: Cooksley WG, Piratvisuth T, Lee SD. et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat. 2003 Jul;10(4):298–305. [PubMed: 12823597]
117.: Chan HL, Hui AY, Wong VW. et al. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology. 2005 Jun;41(6):1357–64. [PubMed: 15880608]
118.: Chan HL, Tse AM, Zhang MD. et al. Genetic polymorphisms of interleukin-1-beta in association with sustained response to anti-viral treatment in chronic hepatitis B in Chinese. Aliment Pharmacol Ther. 2006 Jun 15;23(12):1703–11. [PubMed: 16817913]
119.: van Zonneveld M, Flink HJ, Verhey E. et al. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther. 2005 May 1;21(9):1163–71. [PubMed: 15854180]
120.: Flink HJ, Sprengers D, Hansen BE. et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. Gut. 2005 Nov;54(11):1604–9. [PMC free article: PMC1774756] [PubMed: 15923670]
121.: Flink HJ, Hansen BE, Heathcote EJ. et al. Successful treatment with peginterferon alfa-2b of HBeAg-positive HBV non-responders to standard interferon or lamivudine. Am J Gastroenterol. 2006 Nov;101(11):2523–9. [PubMed: 17029610]
122.: Flink HJ, van Zonneveld M, Hansen BE. et al. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol. 2006 Feb;101(2):297–303. [PubMed: 16454834]
123.: ter Borg MJ, van Zonneveld M, Zeuzem S. et al. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. Hepatology. 2006 Sep;44(3):721–7. [PubMed: 16941701]
124.: Buster EH, Hansen BE, Buti M. et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology. 2007 Aug;46(2):388–94. [PubMed: 17604363]
125.: van Zonneveld M, Zondervan PE, Cakaloglu Y. et al. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. Liver Int. 2006 May;26(4):399–405. [PubMed: 16629642]
126.: Westland C, Delaney Wt, Yang H. et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil. Gastroenterology. 2003 Jul;125(1):107–16. [PubMed: 12851876]
127.: Di Marco V, Lo Iacono O, Camma C. et al. The long-term course of chronic hepatitis B. Hepatology. 1999 Jul;30(1):257–64. [PubMed: 10385664]
128.: Brunetto MR, Oliveri F, Coco B. et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol. 2002 Feb;36(2):263–70. [PubMed: 11830339]
129.: Hui CK, Leung N, Shek WH. et al. Changes in Liver Histology as a “Surrogate” End Point of Antiviral Therapy for Chronic HBV Can Predict Progression to Liver Complications. J Clin Gastroenterol. 2008 May/June;42(5):533–8. [PubMed: 18344885]
130.: Papatheodoridis GV, Dimou E, Dimakopoulos K. et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology. 2005 Jul;42(1):121–9. [PubMed: 15962291]
131.: Papatheodoridis GV, Petraki K, Cholongitas E. et al. Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B. J Viral Hepat. 2005 Mar;12(2):199–206. [PubMed: 15720536]
132.: Lampertico P, Del Ninno E, Vigano M. et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology. 2003 Apr;37(4):756–63. [PubMed: 12668967]

Bookshelf ID: NBK38694

Contents

< Prev Next >

PubReader
Print View
Cite this Page
Wilt TJ, Shamliyan T, Shaukat A, et al. Management of Chronic Hepatitis B. Rockville (MD): Agency for Healthcare Research and Quality (US); 2008 Oct. (Evidence Reports/Technology Assessments, No. 174.) Appendix E Tables and Figures.

Other titles in these collections

Recent Activity

Clear Turn Off Turn On

Appendix E Tables and Figures - Management of Chronic Hepatitis B
Appendix E Tables and Figures - Management of Chronic Hepatitis B

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Bookshelf

Management of Chronic Hepatitis B.

Appendix E Tables and Figures

References for Appendix E

Views

Other titles in these collections

Recent Activity